Alberto Lazarowski
Overview
Explore the profile of Alberto Lazarowski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
826
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zeballos L, Garcia-Peral C, Ledesma M, Auzmendi J, Lazarowski A, Lopez D
Int J Mol Sci
. 2025 Mar;
26(5).
PMID: 40076950
Epilepsy is a multifaceted neurological disorder characterized by recurrent seizures and associated with molecular and immune alterations in key brain regions. The GASH/Sal (Genetic Audiogenic Seizure Hamster, Salamanca), a genetic...
2.
Gomez C, Borda N, Moscovicz F, Fernandez F, Lazarowski A, Auzmendi J
Curr Pharm Des
. 2024 Jun;
30(28):2222-2228.
PMID: 38874045
Background: Cannabidiol (CBD) is the principal non-hallucinogenic compound of Cannabis plants with high clinical interest because CBD has been described as having anti-inflammatory, analgesic and anticonvulsant properties. CBD is considered...
3.
Lairion F, Carbia C, Chiesa I, Saporito-Magrina C, Borda N, Lazarowski A, et al.
Pharmaceuticals (Basel)
. 2023 Oct;
16(10).
PMID: 37895972
The extracellular purinergic agonist uridine diphosphate glucose (UDP-G) activates chemotaxis of human neutrophils (PMN) and the recruitment of PMN at the lung level, via P2Y14 purinergic receptor signaling. This effect...
4.
Akyuz E, Lazarowski A, de Cabo C, Godlevsky L, Shaikh M, Doganyigit Z
Front Neurol
. 2023 Aug;
14:1263539.
PMID: 37638194
No abstract available.
5.
Salas-Hernandez A, Galleguillos M, Carrasco M, Lopez-Cortes A, Redal M, Fonseca-Mendoza D, et al.
Front Pharmacol
. 2023 May;
14:1175737.
PMID: 37251329
Pharmacogenomics (PGx) is considered an emergent field in developing countries. Research on PGx in the Latin American and the Caribbean (LAC) region remains scarce, with limited information in some populations....
6.
Lopez-Cortes A, Esperon P, Martinez M, Redal M, Lazarowski A, Varela N, et al.
Front Pharmacol
. 2023 May;
14:1211712.
PMID: 37205907
No abstract available.
7.
Akyuz E, Saleem Q, Sari C, Auzmendi J, Lazarowski A
Curr Med Chem
. 2023 Feb;
PMID: 36815654
Epilepsy is a chronic neurological degenerative disease with a high incidence, affecting all age groups. Refractory Epilepsy (RE) occurs in approximately 30-40% of cases with a higher risk of sudden...
8.
Esperon P, Martinez M, Redal M, Lazarowski A, Lopez-Cortes A, Varela N, et al.
Front Pharmacol
. 2022 Jan;
12:833000.
PMID: 35087412
No abstract available.
9.
Czornyj L, Auzmendi J, Lazarowski A
Epilepsia Open
. 2021 Sep;
7 Suppl 1:S34-S46.
PMID: 34542938
The multidrug-resistance (MDR) phenotype is typically observed in patients with refractory epilepsy (RE) whose seizures are not controlled despite receiving several combinations of more than two antiseizure medications (ASMs) directed...
10.
Serral F, Castello F, Sosa E, Pardo A, Palumbo M, Modenutti C, et al.
Front Pharmacol
. 2021 Jun;
12:647060.
PMID: 34177572
Decades of successful use of antibiotics is currently challenged by the emergence of increasingly resistant bacterial strains. Novel drugs are urgently required but, in a scenario where private investment in...